Board of Directors

Peter Barrett
Chairman
Peter Barrett is a partner in the life sciences group and focuses on investments in therapeutics and medical technologies that significantly change the medical management of patients.

At Atlas, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Peter leverages his background in corporate business development to provide strategic and negotiating guidance to his portfolio; he was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals (NASDAQ: SCLN). He is currently chairman of Harbour Antibodies and Zafgen, and also serves on the boards of Mnemosyne Pharmaceuticals, InfaCare, JenaValve, and Vitae Pharmaceuticals. Peter was previously on the boards of past Atlas companies SciClone Pharmaceuticals, Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), and Archemix (acquired by Baxter).

Prior to joining Atlas in 2002, Peter was co-founder, executive vice president, and chief business officer of Celera Genomics. Within two years of its founding, Celera announced the first successful sequencing of the human genome. Peter helped launch Celera as a publicly traded entity in 1999. He led Celera’s strategic alliances and acquisitions, and participated in raising nearly $1 billion in capital for the company.

Prior to Celera, Peter held senior management positions at PerkinElmer, most recently serving as vice president, corporate planning and business development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships, and acquisitions.

Peter is currently vice chairman of the advisory council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as adjunct professor at the Barnett Institute. He also serves as president of the Autism Consortium, a non-profit institution, is a member of the research council at Boston Children’s Hospital, and serves on the board of PerkinElmer.

Peter received a B.S. in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a Ph.D. in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program.

Outside the office, Peter is a competitive sailor and skier, theater lover, and frustrated actor.
JC Gutiérrez-Ramos , Ph.D.
Dr. Gutiérrez-Ramos is Chief Executive Officer of Synlogic. Dr. Gutiérrez-Ramos joined Synlogic from Pfizer, where he served as Group Senior Vice President and global head of the BioTherapeutics Research. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. He previously held the position of Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics. Prior to his work in the pharmaceutical industry, JC held senior leadership positions at several biotech companies; He was Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. where he led a significant efforts focused on the discovery of novel protein therapeutics and peptides for autoimmune disease, including multiple sclerosis and diabetes. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery. In that capacity he was responsible for advancing preclinical candidates in inflammation and immunology into human clinical trials and advancing compounds (small molecules and antibodies) from discovery through clinical development. JC began his career in academia as part of the Faculty at the Genetics department of Harvard Medical School. He was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Plank Institute in Freiburg, Germany. He has co-authored more than 150 peer-reviewed publications. JC holds a PhD in immunochemistry from the Autonoma University in Madrid, Spain.
Chau Q. Khuong
Chau Quang Khuong has been at OrbiMed Advisors LLC since 2003 and is Private Equity Partner. Mr. Khuong gained experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He has been an active investor in drug development and medical device companies across many therapeutic areas and technology disciplines. He has been a Board of Directors representative at numerous OrbiMed investments, including currently Aerpio Therapeutics, Inc., Graybug Vision, Inspire Medical Systems, Intellia, Nabriva (NASDAQ: NBVR), NextCure, Otonomy, Inc. (NASDAQ: OTIC), Pieris Pharmaceuticals (NASDAQ: PIRS), and ReViral. Mr. Khuong holds a B.S. in molecular, cellular and developmental biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.
Nick Leschly
Nick Leschly is CEO of bluebird bio, Inc. (NASDAQ: BLUE) and has served in this role since September 2010. Previously, Nick was a partner and founding member of Third Rock Ventures in 2007. He played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc.

Prior to joining Third Rock, Nick worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product leader for VELCADE.

Nick received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO).
Ed Mathers
Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Envisia Therapeutics, Liquidia Technologies, Lumos Pharmaceuticals, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals. Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board, Southeast Bio board, and the NC State Physical and Mathematical Sciences Foundation board.

Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.
Charlotte Hubbert, Ph.D. (Observer)
Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing in innovative and technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.

Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).